Tumour maintenance is mediated by eNOS

被引:241
作者
Lim, Kian-Huat [1 ]
Ancrile, Brooke B. [1 ]
Kashatus, David F. [1 ]
Counter, Christopher M. [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Dept Radiat Oncol, Durham, NC 27710 USA
关键词
D O I
10.1038/nature06778
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Tumour cells become addicted to the expression of initiating oncogenes like Ras, such that loss of oncogene expression in established tumours leads to tumour regression(1). HRas, NRas or KRas are mutated to remain in the active GTP- bound oncogenic state in many cancers(2). Although Ras activates several proteins to initiate human tumour growth, only PI3K, through activation of protein kinase B ( PKB; also known as AKT), must remain activated by oncogenic Ras to maintain this growth63. Here we show that blocking phosphorylation of the AKT substrate, endothelial nitric oxide synthase ( eNOS or NOS3), inhibits tumour initiation and maintenance. Moreover, eNOS enhances the nitrosylation and activation of endogenous wild- type Ras proteins, which are required throughout tumorigenesis. We suggest that activation of the PI3K - AKT - eNOS -( wild- type) Ras pathway by oncogenic Ras in cancer cells is required to initiate and maintain tumour growth.
引用
收藏
页码:646 / U11
页数:5
相关论文
共 35 条
[1]   Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis [J].
Ancrile, Brooke ;
Lim, Kian-Huat ;
Counter, Christopher M. .
GENES & DEVELOPMENT, 2007, 21 (14) :1714-1719
[2]   Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor [J].
Brunet, A ;
Bonni, A ;
Zigmond, MJ ;
Lin, MZ ;
Juo, P ;
Hu, LS ;
Anderson, MJ ;
Arden, KC ;
Blenis, J ;
Greenberg, ME .
CELL, 1999, 96 (06) :857-868
[3]   Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras [J].
deRooij, J ;
Bos, JL .
ONCOGENE, 1997, 14 (05) :623-625
[4]   Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation [J].
Dimmeler, S ;
Fleming, I ;
Fisslthaler, B ;
Hermann, C ;
Busse, R ;
Zeiher, AM .
NATURE, 1999, 399 (6736) :601-605
[5]   Targeting ras signalling pathways in cancer therapy [J].
Downward, J .
NATURE REVIEWS CANCER, 2003, 3 (01) :11-22
[6]   Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development [J].
Esteban, LM ;
Vicario-Abejón, C ;
Fernández-Salguero, P ;
Fernández-Medarde, A ;
Swaminathan, N ;
Yienger, K ;
Lopez, E ;
Malumbres, M ;
McKay, R ;
Ward, JM ;
Pellicer, A ;
Santos, E .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (05) :1444-1452
[7]   Wild-type NRas and KRas perform distinct functions during transformation [J].
Fotiadou, Poppy P. ;
Takahashi, Chiaki ;
Rajabi, Hasan N. ;
Ewen, Mark E. .
MOLECULAR AND CELLULAR BIOLOGY, 2007, 27 (19) :6742-6755
[8]   The role of nitric oxide in tumour progression [J].
Fukumura, Dai ;
Kashiwagi, Satoshi ;
Jain, Rakesh K. .
NATURE REVIEWS CANCER, 2006, 6 (07) :521-534
[9]   Regulation of endothelium-derived nitric oxide production by the protein kinase Akt [J].
Fulton, D ;
Gratton, JP ;
McCabe, TJ ;
Fontana, J ;
Fujio, Y ;
Walsh, K ;
Franke, TF ;
Papapetropoulos, A ;
Sessa, WC .
NATURE, 1999, 399 (6736) :597-601
[10]   Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer [J].
Giuriato, S ;
Rabin, K ;
Fan, AC ;
Shachaf, CM ;
Felsher, DW .
SEMINARS IN CANCER BIOLOGY, 2004, 14 (01) :3-11